Hanmi Pharm signs 3.2 tln-won licensing deal with Roche's Genentech for obesity drug candidate
--------------------------------------------------------------------
Source: South Korea
Published: 2026-08-24 16:00 UTC+10:00
Section: General
Factuality Score: 100
Opinion Category: Neutral
Topics: Health, South Korea, Elections, Drugs
--------------------------------------------------------------------
Snippet:
SEOUL, Aug. 24 (Yonhap) -- Hanmi Pharm. Co., a South Korean pharmaceutical company, said Monday it has signed a 3.2 trillion-won (US$2.3 billion) licensing deal with Genentech Inc., a U.S.-based member of the Roche Group, for an obesity drug candidate designed to reduce body fat while preserving and increasing muscle mass.
--------------------------------------------------------------------